Use of abiraterone in castration resistant prostate cancer nursing essay
Treatment with abiraterone abi-acetate prolongs survival in castration-resistant prostate cancer CRPC. Resistance to ABI occurs invariably, probably due in part to the upregulation of ABI. Oral abiraterone acetate, in combination with prednisone-prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer CRPC who have previously received docetaxel-containing chemotherapy. Abiraterone acetate is designed to specifically inhibit cytochrome P450 CYP 17A1, which is essential. This review will discuss the pathophysiology of prostate cancer, followed by the mechanism of action and pharmacokinetic properties of abiraterone. The review also discusses the role of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Keywords: CYP17 drug resistance enzalutamide glucocorticoid. Until recently, treatment options for castration-resistant prostate cancer CRPC were limited to only the chemotherapeutic agent docetaxel, which demonstrated a survival benefit over palliative chemotherapy. Abiraterone acetate AA is an orally available, potent irreversible inhibitor of the adrenal microsomal enzyme cytochrome. INTRODUCTION. Prostate cancer develops resistance to serum androgen suppression in virtually all patients with advanced disease. Upregulating AR expression of the androgen receptor and autonomous synthesis of androgens by neoplastic prostate epithelium, either de novo from cholesterol or through metabolism of adrenal precursors, PTEN loss and abnormalities in PI3K AKT signaling kinases associated with poorer response to abiraterone acetate AA in mCRPC with metastatic castration-resistant prostate cancer. In this study, we assessed the antitumor activity of the AKT inhibitor capivasertib in combination with enzalutamide in mCRPC with prior progression on AA and prostate cancer PC is the most common solid cancer and the second most common cause of cancer-related death in men despite adequate therapy. , the disease eventually progresses to castration. The androgen receptor remains the key player in patients with castration-resistant prostate cancer CRPC. Available agents that can block early androgen production by the adrenal gland have limited activity and can lead to significant toxicities. Abiraterone acetate, a pregnenolone analogue, is a small molecule that irreversibly inhibits CYP17. Longer duration of postdiagnostic statin use also appears to improve prostate cancer biomarkers in clinical trials. Studies of statins and prostate cancer survival among all men support a background. In the CARD study NCT02485691, cabazitaxel significantly improved clinical outcomes compared with abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signaling targeted inhibitor. However, some patients received docetaxel or the, The European Medicines Agency Review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after chemotherapy with docetaxel and in chemotherapy-naïve disease.